Latest Research, Industry, Medical and Scientific News
Patients with COVID-19 infection are at increased risk of developing new or worsening symptoms of overactive bladder (OAB), according to data presented at the American Urological Association’s annual meeting in 2022 in New Orleans, Louisiana. Ly Hoang Roberts, MD, of Oakland University, Royal Oak, Michigan, and colleagues noted that they were the first American group to identify de novo genitourinary symptoms, such as frequency, urgency, nocturia, and pain / pressure in people with previous COVID 19 infection. They called this condition COVID-19 associated cystitis (CAC). Read more.
Source: Community 99, May 15, 2022
First Quality Products, Inc. is launching a new technology for bladder control pads called MaxSorb+ Zone, providing enhanced rapid absorption to help keep skin dry all day and support skin health. Pads that use First Quality’s MaxSorb+ Zone absorb up to 50% faster compared to previous Prevail bladder control pads. Read more.
Source: Nonwovens Industry, April 28, 2022
For women with frequent urine leakage, a newer and simpler “sling” surgery works as well as the standard version, according to a new clinical trial. The study involved women with stress urinary incontinence, where movement that puts pressure on the abdomen — such as running, lifting, coughing or laughing — causes urine leakage. When the condition is severe, surgery may be recommended. Read more.
Source: UPI, April 1, 2022
After receiving an FDA approval last month in bladder and bowel incontinence for its neuromodulation device implanted in the lower back, Medtronic isn’t resting on its laurels. It has begun a clinical trial of a similar system placed near the ankle, which the company described as a more convenient option that may make the therapy available to more people. The medtech giant announced that its first patients have received implants in the pivotal study, with neurostimulators that tap into the posterior tibial nerve running up the back of the leg, to transmit electrical pulses that aim to help regulate an overactive bladder. Read more.
Source: Fierce Biotech, March 25, 2022
Virtual Research Organisation (VRO) ObvioHealth may have completed the first ever fully virtual urogynaecology study, in the form of a medical device clinical trial of Renovia’s digital intravaginal device Leva for female stress urinary incontinence. Urinary incontinence is unintentional passing of urine, which affects one in four women, particularly 75% of women above the age 65 reporting urine leakage. Pelvic floor muscle training (PMFT), commonly known as Kegels, is the standard among noninvasive approaches for urinary incontinence. However, 75% of women perform the exercises incorrectly by engaging wrong muscle groups or following a wrong routine. Leva is designed to help users how to preform Kegels more effectively. Read more.
Source: Clinical Trials Arena, March 17, 2022
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has approved its newly developed, long-lived, recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS). Read more.
Source: Business Wire, March 7, 2022